ANDA 205756, held by Rising Pharmaceuticals. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 205756 (Methylphenidate Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Nov 7, 2016, with 4 approved supplements and 0 published complete response letters.
Methylphenidate Hydrochloride Chewable Tablets is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older Narcolepsy
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 7, 2016 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride2.5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Rx |
| Apr 29, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 13, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 22, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 7, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters